Extrait de Serenoa repens SEREVELLE 160 mg par jour
1 étude, 60 participants · Alopécie androgénétique · Hommes et femmes
L'extrait de Serenoa repens SEREVELLE à 160 mg par jour a été testé contre placebo dans un seul essai de fiabilité moyenne, chez 60 hommes et femmes de 25 à 65 ans se plaignant d'un affinement des cheveux (Ablon 2026). En 26 semaines, le nombre de cheveux comptés sur photo passe de 315,6 à 340,7 sur la zone cible, et 20 % des participants (8 sur 40) sont nettement améliorés, des résultats significativement meilleurs que sous placebo. Aucun effet indésirable n'est rapporté (0 sur 40). Un essai unique, à confirmer.
Piste explorée
Ce traitement n'a été mesuré que dans une seule étude par critère : il n'existe pas encore assez d'essais pour en tirer une conclusion. Les résultats ci-dessous sont des indices, à lire avec leurs limites.
Les résultats
Critères mesurés dans une seule étude : chaque ligne est un résultat isolé.
Efficacité
- Amélioration marquée20 % (8 sur 40) face à Placebo
Voir la citation
Hair growth, n (%)b Greatly increased Moderately increased 8 (20) 1 (5) Slightly increased 20 (50) 4 (20) No change 6 (15) 7 (35) Slightly decreased 6 (15) 6 (30) Moderately decreased 2 (10)
Citation complémentaire (inclusion)
Eligible participants were healthy men and women, aged 25–65 years, of any Fitzpatrick Skin Type, who reported con- cerns about hair thinning and expressed interest in improving hair density and appearance. Male subjects qualified if they pre- sented with hair loss patterns I, II, IIA, III, III vertex, or IV on the Investigator- rated Norwood Classification Scale [9]. Female subjects were required to have thinning patterns corresponding to grades I- 1, I- 2, or I- 3 on the Savin Pictorial Scale [10].
Citation complémentaire (significativite)
bA two- tailed binomial test of two proportions found differences in investigator improved hair quality ratings between supplement groups at Day 180 to favor the active group at each assessment, p < 0.001.
Ablon G. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. Journal of Cosmetic Dermatology 2026, DOI 10.1111/jocd.70717. Citation sous licence CC-BY.
- Nombre de cheveux sur la zone cible, comptage photographique315,6 → 340,7 cheveux sur la zone cible face à Placebo
Voir la citation
Total hair counts Mean (SD) 315.6 (48.9) 340.7 (51.0)b,d Median (min, max) 318.0 (191, 452) 344.0 (255, 471) Change (SD) 25.1 (27.7)
Citation complémentaire (inclusion)
Eligible participants were healthy men and women, aged 25–65 years, of any Fitzpatrick Skin Type, who reported con- cerns about hair thinning and expressed interest in improving hair density and appearance. Male subjects qualified if they pre- sented with hair loss patterns I, II, IIA, III, III vertex, or IV on the Investigator- rated Norwood Classification Scale [9]. Female subjects were required to have thinning patterns corresponding to grades I- 1, I- 2, or I- 3 on the Savin Pictorial Scale [10].
Citation complémentaire (significativite)
sity rose +25.1 (27.7) vs. –12.2 (38.8) (p < 0.001; 306% greater improvement). Subgroup analyses at Day 180 corroborated these
Ablon G. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. Journal of Cosmetic Dermatology 2026, DOI 10.1111/jocd.70717. Citation sous licence CC-BY.
- Patients stabilisés, sans gain ni perte15 % (6 sur 40) face à Placebo
Voir la citation
Hair growth, n (%)b Greatly increased Moderately increased 8 (20) 1 (5) Slightly increased 20 (50) 4 (20) No change 6 (15) 7 (35) Slightly decreased 6 (15) 6 (30) Moderately decreased 2 (10)
Citation complémentaire (inclusion)
Eligible participants were healthy men and women, aged 25–65 years, of any Fitzpatrick Skin Type, who reported con- cerns about hair thinning and expressed interest in improving hair density and appearance. Male subjects qualified if they pre- sented with hair loss patterns I, II, IIA, III, III vertex, or IV on the Investigator- rated Norwood Classification Scale [9]. Female subjects were required to have thinning patterns corresponding to grades I- 1, I- 2, or I- 3 on the Savin Pictorial Scale [10].
Citation complémentaire (significativite)
bA two- tailed binomial test of two proportions found differences in investigator improved hair quality ratings between supplement groups at Day 180 to favor the active group at each assessment, p < 0.001.
Ablon G. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. Journal of Cosmetic Dermatology 2026, DOI 10.1111/jocd.70717. Citation sous licence CC-BY.
Tolérance
- Incidence d'un effet indésirable, toutes natures confondues0 % (0 sur 40) face à Placebo
Voir la citation
There were no reported local or systemic adverse events consid-
Citation complémentaire (inclusion)
Eligible participants were healthy men and women, aged 25–65 years, of any Fitzpatrick Skin Type, who reported con- cerns about hair thinning and expressed interest in improving hair density and appearance. Male subjects qualified if they pre- sented with hair loss patterns I, II, IIA, III, III vertex, or IV on the Investigator- rated Norwood Classification Scale [9]. Female subjects were required to have thinning patterns corresponding to grades I- 1, I- 2, or I- 3 on the Savin Pictorial Scale [10].
Ablon G. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. Journal of Cosmetic Dermatology 2026, DOI 10.1111/jocd.70717. Citation sous licence CC-BY.
Les études
- Ablon 2026 · Essai randomisé, risque de biais modéré. The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results Financement : Non declare ; produit de Valensa International